RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.